Radiopharmaceuticals have achieved a breakthrough development format in the Russian Federation, and this has influenced mortality rates from cancer. Russian Minister of Health Mikhail Murashko announced this at the VIII annual Biotechmed forum, which is currently being held in Sochi on October 9-10.
“We are committed to expanding our assistance even further, particularly in the field of oncology and cardiovascular diseases. We have achieved a breakthrough development format for radiopharmaceuticals, and this has affected mortality rates from cancer. There is a direction on rheumatoid diseases, and there are also a number of positive changes in these areas. A number of other drugs are currently undergoing clinical trials; there is hope that they will be successful; as soon as these drugs enter the market, the landscape of therapy will change. This is both a reduction in disability and an increase in the quality of life,” the minister noted.
“Implementing a transparent tariff policy enables us to enhance accessibility and expand the availability of vital treatments such as antitumor therapy,” he explained. “Through the development of import substitution and procurement programs, we have successfully achieved significant cost savings. In fact, our centralized procurement and order formation saved us a remarkable 12.5% last year,” emphasized Mikhail Murashko.
